

## Author Index Volume 32 (2010)

- Akgul, G., see Kaarbø, M. (1,2) 11– 27  
Alinger, B., see Di Fazio, P. (4) 285–300  
Allonca, E., see Hermsen, M.A. (4) 275–283
- Balbín, M., see Hermsen, M.A. (4) 275–283  
Balsari, A., see Lucci, M.A. (5,6) 361–372  
Barisione, G., see Corrias, M.V. (1,2) 77– 86  
Barraclough, D.L., S. Sewart, P.S. Rudland, B.S. Shoker, D.R. Sibson, R. Barraclough and M.P.A. Davies,  
Microarray analysis of suppression subtracted hybridisation libraries identifies genes associated with  
breast cancer progression (1,2) 87– 99  
Barraclough, R., see Barraclough, D.L. (1,2) 87– 99  
Berezin, V., see Xu, R. (4) 259–274  
Bestebroer, J., see Walenkamp, A.M.E. (1,2) 1– 10  
Bock, E., see Xu, R. (4) 259–274  
Boer, I.G.J., see Walenkamp, A.M.E. (1,2) 1– 10  
Brandi, M.L., see Tognarini, I. (5,6) 331–343
- Carvalho, R., see Milne, A.N. (5,6) 347–359  
Castigliengo, D., see Moelans, C.B. (1,2) 149–155  
Cavallero, A., see Donadini, A. (5,6) 373–383  
Cavalli, L., see Tognarini, I. (5,6) 331–343  
Cavalli, T., see Tognarini, I. (5,6) 331–343  
Chao, W., see Wu, A. (5,6) 313–329  
Chung, H.-J., see Weber, A. (1,2) 121–130  
Claessen, M.M.H., M.E.I. Schipper, B. Oldenburg, P.D. Siersema, G.J.A. Offerhaus and F.P. Vlegaar,  
WNT-pathway activation in IBD-associated colorectal carcinogenesis: Potential biomarkers for colonic  
surveillance (4) 303–310  
Colli, E., see Tognarini, I. (5,6) 331–343  
Corrias, M.V., C. Gambini, A. Gregorio, M. Croce, G. Barisione, C. Cossu, A. Rossello, S. Ferrini and  
M. Fabbi, Different subcellular localization of ALCAM molecules in neuroblastoma: Association with  
relapse (1,2) 77– 86  
Corver, W.E., see Milne, A.N. (5,6) 347–359  
Cossu, C., see Corrias, M.V. (1,2) 77– 86  
Croce, M., see Corrias, M.V. (1,2) 77– 86
- Davies, M.P.A., see Barraclough, D.L. (1,2) 87– 99  
de Bruijn, M.T., see van Houdt, W.J. (4) 245–257  
de Haas, C.J.C., see Walenkamp, A.M.E. (1,2) 1– 10  
de Leng, W.W., see Milne, A.N. (5,6) 347–359  
de Weger, R.A., see Moelans, C.B. (1,2) 149–155  
Di Fazio, P., R. Schneider-Stock, D. Neureiter, K. Okamoto, T. Wissniowski, S. Gahr, K. Quint,  
M. Meissnitzer, B. Alinger, R. Montalbano, G. Sass, B. Hohenstein, E.G. Hahn and M. Ocker, The pan-  
deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative  
pathways of apoptosis (4) 285–300

- Di Nallo, E., see Donadini, A. (5,6) 373–383
- Diamond, J., see Koo, V. (1,2) 67– 76
- Donadini, A., M. Maffei, A. Cavallero, M. Pentenero, D. Malacarne, E. Di Nallo, M. Truini, R. Navone, P. Mereu, M. Scala, A. Santelli, S. Gandolfo and W. Giaretti, Oral cancer genesis and progression: DNA near-diploid aneuploidization and endoreduplication by high resolution flow cytometry (5,6) 373–383
- Eijssink, J.J.H., see Yang, N. (1,2) 131–143
- El Mekabaty, A., see Koo, V. (1,2) 67– 76
- Emmink, B.L., see van Houdt, W.J. (4) 245–257
- Ericson, K., see Wu, A. (5,6) 313–329
- Fabbi, M., see Corrias, M.V. (1,2) 77– 86
- Ferrini, S., see Corrias, M.V. (1,2) 77– 86
- Franzke, A., see Ivanyi, P. (1,2) 101–108
- Gabbert, H.E., see Grabsch, H. (1,2) 57– 65
- Gabbert, H.E., see Heikaus, S. (1,2) 29– 42
- Gahr, S., see Di Fazio, P. (4) 285–300
- Galli, G., see Tognarini, I. (5,6) 331–343
- Gambini, C., see Corrias, M.V. (1,2) 77– 86
- Gandolfo, S., see Donadini, A. (5,6) 373–383
- Ganser, A., see Ivanyi, P. (1,2) 101–108
- Garcia-Inclán, C., see Hermsen, M.A. (4) 275–283
- Giaretti, W., see Donadini, A. (5,6) 373–383
- Gozzini, A., see Tognarini, I. (5,6) 331–343
- Grabe, N., B. Lahrmann, T. Pommerencke, M. von Knebel Doeberitz, M. Reuschenbach and N. Wentzensen, A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides (1,2) 109–119
- Grabsch, H., S. Sivakumar, S. Gray, H.E. Gabbert and W. Müller, HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series (1,2) 57– 65
- Graf, M., see Scholten, K.B.J. (1,2) 43– 56
- Gray, S., see Grabsch, H. (1,2) 57– 65
- Gregorio, A., see Corrias, M.V. (1,2) 77– 86
- Grimbergen, A., see Hermsen, M.A. (4) 275–283
- Hahn, E.G., see Di Fazio, P. (4) 285–300
- Halvorsen, T., see Kaarbø, M. (1,2) 11– 27
- Hamilton, P., see Koo, V. (1,2) 67– 76
- Heikaus, S., I. Pejin, H.E. Gabbert, U. Ramp and C. Mahotka, PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs (1,2) 29– 42
- Heitzmann, D., see Weber, A. (1,2) 121–130
- Hermsen, M.A., M.A. Sevilla, J.L. Llorente, M.M. Weiss, A. Grimbergen, E. Allonca, C. Garcia-Inclán, M. Balbín and C. Suárez, Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management (4) 275–283
- Hohenstein, B., see Di Fazio, P. (4) 285–300
- Hollema, H., see Yang, N. (1,2) 131–143
- Hoogwater, F.J.H., see van Houdt, W.J. (4) 245–257
- Hooijberg, E., see Scholten, K.B.J. (1,2) 43– 56
- Ivanyi, P., M. Morgan, W. Piao, S.N. Ukena, K. Steube, A. Ganser and A. Franzke, Pre T-cell receptor alpha (pT $\alpha$ ) expression patterns and functional analysis in human T-cell lymphoblastic leukemia (1,2) 101–108
- Kaarbø, M., Ø.L. Mikkelsen, L. Malerød, S. Qu, V.H. Lobert, G. Akgul, T. Halvorsen, G.M. Mælandsmo and F. Saatcioglu, PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells (1,2) 11– 27
- Kibbelaar, R.E., see Moelans, C.B. (1,2) 149–155
- Koo, V., A. El Mekabaty, P. Hamilton, P. Maxwell, O. Sharaf, J. Diamond, J. Watson and K. Williamson, Novel *in vitro* assays for the characterization of EMT in tumorigenesis (1,2) 67– 76

- Kramer, D., see Scholten, K.B.J. (1,2) 43–56  
 Kranenburg, O., see van Houdt, W.J. (4) 245–257  
 Kruizinga, R., see Walenkamp, A.M.E. (1,2) 1–10
- Lahrman, B., see Grabe, N. (1,2) 109–119  
 Leguit, R., see Milne, A.N. (5,6) 347–359  
 Lendvai, Á., see Yang, N. (1,2) 131–143  
 Llorente, J.L., see Hermsen, M.A. (4) 275–283  
 Lobert, V.H., see Kaarbø, M. (1,2) 11–27  
 Low, W.C., see Wu, A. (5,6) 313–329  
 Lucci, M.A., R. Orlandi, T. Triulzi, E. Tagliabue, A. Balsari and E. Villa-Moruzzi, Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors (5,6) 361–372
- Mælandsmo, G.M., see Kaarbø, M. (1,2) 11–27  
 Maffei, M., see Donadini, A. (5,6) 373–383  
 Mahotka, C., see Heikaus, S. (1,2) 29–42  
 Malacarne, D., see Donadini, A. (5,6) 373–383  
 Malerød, L., see Kaarbø, M. (1,2) 11–27  
 Man, S., see Scholten, K.B.J. (1,2) 43–56  
 Marini, F., see Tognarini, I. (5,6) 331–343  
 Martinetti, V., see Tognarini, I. (5,6) 331–343  
 Maxwell, P., see Koo, V. (1,2) 67–76  
 Meijer, C.J.L.M., see Scholten, K.B.J. (1,2) 43–56  
 Meijer, G., Editorial: The second wave of quantitative pathology (1,2) 147–148  
 Meissnitzer, M., see Di Fazio, P. (4) 285–300  
 Mereu, P., see Donadini, A. (5,6) 373–383  
 Mikkelsen, Ø.L., see Kaarbø, M. (1,2) 11–27  
 Milne, A.N., R. Leguit, W.E. Corver, F.H.M. Morsink, M. Polak, W.W. de Leng, R. Carvalho and G.J.A. Offerhaus, Loss of *CDC4/FBXW7* in gastric carcinoma (5,6) 347–359  
 Moelans, C.B., R.E. Kibbelaar, M.C. van den Heuvel, D. Castiglione, R.A. de Weger and P.J. van Diest, Validation of a fully automated HER2 staining kit in breast cancer (1,2) 149–155  
 Montalbano, R., see Di Fazio, P. (4) 285–300  
 Morgan, M., see Ivanyi, P. (1,2) 101–108  
 Morsink, F.H.M., see Milne, A.N. (5,6) 347–359  
 Müller, W., see Grabsch, H. (1,2) 57–65
- Navone, R., see Donadini, A. (5,6) 373–383  
 Nesi, G., see Tognarini, I. (5,6) 331–343  
 Neureiter, D., see Di Fazio, P. (4) 285–300  
 Nijhuis, E.R., see Yang, N. (1,2) 131–143
- Ocker, M., see Di Fazio, P. (4) 285–300  
 Offerhaus, G.J.A., see Claessen, M.M.H. (4) 303–310  
 Offerhaus, G.J.A., see Milne, A.N. (5,6) 347–359  
 Okamoto, K., see Di Fazio, P. (4) 285–300  
 Oldenburg, B., see Claessen, M.M.H. (4) 303–310  
 Orlandi, R., see Lucci, M.A. (5,6) 361–372
- Paglierani, M., see Tognarini, I. (5,6) 331–343  
 Pejin, I., see Heikaus, S. (1,2) 29–42  
 Pentenero, M., see Donadini, A. (5,6) 373–383  
 Piao, W., see Ivanyi, P. (1,2) 101–108  
 Polak, M., see Milne, A.N. (5,6) 347–359  
 Pommerencke, T., see Grabe, N. (1,2) 109–119  
 Povlsen, G.K., see Xu, R. (4) 259–274

- Qu, S., see Kaarbø, M. (1,2) 11– 27
- Quint, K., see Di Fazio, P. (4) 285–300
- Raats, D., see van Houdt, W.J. (4) 245–257
- Ramp, U., see Heikaus, S. (1,2) 29– 42
- Reuschenbach, M., see Grabe, N. (1,2) 109–119
- Rinkes, I.H.M.B., see van Houdt, W.J. (4) 245–257
- Rossello, A., see Corrias, M.V. (1,2) 77– 86
- Rudland, P.S., see Barraclough, D.L. (1,2) 87– 99
- Ruizendaal, J.J., see Scholten, K.B.J. (1,2) 43– 56
- Saatcioglu, F., see Kaarbø, M. (1,2) 11– 27
- Santelli, A., see Donadini, A. (5,6) 373–383
- Sass, G., see Di Fazio, P. (4) 285–300
- Scala, M., see Donadini, A. (5,6) 373–383
- Schipper, M.E.I., see Claessen, M.M.H. (4) 303–310
- Schneider-Stock, R., see Di Fazio, P. (4) 285–300
- Schoedl, T., see Scholten, K.B.J. (1,2) 43– 56
- Scholten, K.B.J., J.J. Ruizendaal, M. Graf, T. Schoedl, D. Kramer, C.J.L.M. Meijer, S. Man and E. Hooijberg, Promiscuous behavior of HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification (1,2) 43– 56
- Schuuring, E., see Yang, N. (1,2) 131–143
- Sevilla, M.A., see Hermsen, M.A. (4) 275–283
- Sewart, S., see Barraclough, D.L. (1,2) 87– 99
- Sharaf, O., see Koo, V. (1,2) 67– 76
- Shoker, B.S., see Barraclough, D.L. (1,2) 87– 99
- Sibson, D.R., see Barraclough, D.L. (1,2) 87– 99
- Siersema, P.D., see Claessen, M.M.H. (4) 303–310
- Sivakumar, S., see Grabsch, H. (1,2) 57– 65
- Sorace, S., see Tognarini, I. (5,6) 331–343
- Soroka, V., see Xu, R. (4) 259–274
- Springer, E., see Weber, A. (1,2) 121–130
- Steube, K., see Ivanyi, P. (1,2) 101–108
- Suárez, C., see Hermsen, M.A. (4) 275–283
- Tagliabue, E., see Lucci, M.A. (5,6) 361–372
- Tanini, A., see Tognarini, I. (5,6) 331–343
- Tognarini, I., F. Tonelli, G. Nesi, V. Martineti, G. Galli, A. Gozzini, E. Colli, R. Zonefrati, M. Paglierani, F. Marini, S. Sorace, T. Cavalli, L. Cavalli, A. Tanini and M.L. Brandi, *In vitro* effects of oestrogens, antioestrogens and SERMs on pancreatic solid pseudopapillary neoplasm-derived primary cell culture (5,6) 331–343
- Tonelli, F., see Tognarini, I. (5,6) 331–343
- Triulzi, T., see Lucci, M.A. (5,6) 361–372
- Truini, M., see Donadini, A. (5,6) 373–383
- Ukena, S.N., see Ivanyi, P. (1,2) 101–108
- van den Heuvel, M.C., see Moelans, C.B. (1,2) 149–155
- van der Zee, A.G.J., see Yang, N. (1,2) 131–143
- van Diest, P.J., see Moelans, C.B. (1,2) 149–155
- van Houdt, W.J., M.T. de Bruijn, B.L. Emmink, D. Raats, F.J.H. Hoogwater, I.H.M.B. Rinkes and O. Kranenburg, Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition (4) 245–257
- van Strijp, J.A.G., see Walenkamp, A.M.E. (1,2) 1– 10
- Verheul, H.M., see Walenkamp, A.M.E. (1,2) 1– 10
- Villa-Moruzzi, E., see Lucci, M.A. (5,6) 361–372
- Vleggaar, F.P., see Claessen, M.M.H. (4) 303–310

- Volders, H.H., see Yang, N. (1,2) 131–143  
 von Knebel Doeberitz, M., see Grabe, N. (1,2) 109–119
- Walenkamp, A.M.E., J. Bestebroer, I.G.J. Boer, R. Kruizinga, H.M. Verheul, J.A.G. van Strijp and C.J.C. de Haas, Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets (1,2) 1–10  
 Warth, R., see Weber, A. (1,2) 121–130  
 Watson, J., see Koo, V. (1,2) 67–76  
 Weber, A., H.-J. Chung, E. Springer, D. Heitzmann and R. Warth, The TFIIH subunit p89 (XPB) localizes to the centrosome during mitosis (1,2) 121–130  
 Weiss, M.M., see Hermsen, M.A. (4) 275–283  
 Wentzensen, N., see Grabe, N. (1,2) 109–119  
 Williamson, K., see Koo, V. (1,2) 67–76  
 Wisman, G.B.A., see Yang, N. (1,2) 131–143  
 Wissniowski, T., see Di Fazio, P. (4) 285–300  
 Wu, A., K. Ericson, W. Chao and W.C. Low, NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript (5,6) 313–329
- Xu, R., G.K. Povlsen, V. Soroka, E. Bock and V. Berezin, A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration *in vitro* and xenograft tumor growth *in vivo* (4) 259–274
- Yang, N., E.R. Nijhuis, H.H. Volders, J.J.H. Eijssink, Á. Lendvai, B. Zhang, H. Hollema, E. Schuurung, G.B.A. Wisman and A.G.J. van der Zee, Gene promoter methylation patterns throughout the process of cervical carcinogenesis (1,2) 131–143
- Zhang, B., see Yang, N. (1,2) 131–143  
 Zonefrati, R., see Tognarini, I. (5,6) 331–343